Combined Cell-free DNA and RNA Profiling of the Androgen Receptor: Clinical Utility of a Novel Multianalyte Liquid Biopsy Assay for Metastatic Prostate Cancer
Heidi Fettke, Edmond M Kwan, Maria M Docanto, Patricia Bukczynska, Nicole Ng, Lisa-Jane K Graham, Kate Mahon, Christine Hauser, Winston Tan, Xiao Hong Wang, Zhixin Zhao, Tiantian Zheng, Kemin Zhou, Pan Du, Jianjun Yu, Yong Huang, Shidong Jia, Manish Kohli, Lisa G Horvath, Arun A Azad
European Urology | ELSEVIER | Published : 2020
BACKGROUND: The androgen receptor (AR) remains a critical driver in metastatic castration-resistant prostate cancer (mCRPC). Profiling AR aberrations in both circulating DNA and RNA may identify key predictive and/or prognostic biomarkers in the context of contemporary systemic therapy. OBJECTIVE: To profile AR aberrations in circulating nucleic acids and correlate with clinical outcomes. DESIGN, SETTING, AND PARTICIPANTS: We prospectively enrolled 67 mCRPC patients commencing AR pathway inhibitors (ARPIs; n = 41) or taxane chemotherapy (n = 26). Using a first-in-class next-generation sequencing-based assay, we performed integrated cell-free DNA (cfDNA) and cell-free RNA (cfRNA) profiling fr..View full abstract
Related Projects (2)
Awarded by National Institute of Health
Heidi Fettke: Australian Government Research Training Program (RTP) scholarship. Edmond M. Kwan: NHMRC postgraduate scholarship. Kate Mahon: Movember/Prostate Cancer Foundation of Australia Clinical Scientist Fellow. Lisa G. Horvath: Astellas Investigator-initiated grant, Cancer Institute NSW Translational Program grant. Arun A. Azad: NHMRC project grant, Victorian Cancer Agency Clinical Research Fellowship, Astellas Investigator-initiated grant. Manish Kohli: National Institute of Health (RO1-CA212097).